Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
3(75.0%)
N/A
1(25.0%)
4Total
Phase 4(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04315831Completed

Safety and Effectiveness of Transdermal Buprenorphine in Cancer Pain

Role: lead

NCT03176121Phase 4Completed

Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain

Role: lead

NCT03176199Phase 4Completed

A Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Patients With Moderate to Severe Cancer Pain

Role: lead

NCT04053608Unknown

Human Physiology and Self-Reported Pain Score

Role: collaborator

NCT03155516Not ApplicableUnknown

Effect of Good Pain Management (GPM) Ward Program on Moderate to Severe Cancer Pain Patients

Role: lead

NCT03150602Phase 4Unknown

A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy

Role: lead

All 6 trials loaded